Karen Swales

7PUBLICATIONS
84CO-AUTHORS
Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 27, 2026
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

|Aug 01, 2025
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed

|Jun 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.

Susana Banerjee, Matthew G Krebs, Alastair Greystoke

|Oct 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Christina Guo, Adam Sharp, Bora Gurel

|Sep 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.

Javier Pascual, Joline S J Lim, Iain R Macpherson

|Jul 04, 2020
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors.

Robert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos

Pageof 2

Frequent Collaborators

5 joint publications

Ruth Ruddle

5 joint publications

Udai Banerji

3 joint publications

Christina Yap

3 joint publications

Mona Parmar